Estrone (E1) Lab Results: Normal Range vs. Functional Optimal for Women

What Is Estrone (E1), and Why Does It Get Its Own Lab Test?

Estrone is one of three estrogens your body makes. Estradiol (E2) is the potent, cycle-driving estrogen of your reproductive years. Estriol (E3) spikes during pregnancy. Estrone sits in the middle, biologically weaker than estradiol at the receptor level but clinically important because it becomes your primary circulating estrogen after menopause and because it can be converted back to estradiol in tissues.

Clinicians order an estrone test for reasons that differ by life stage. In a postmenopausal woman, E1 is the main signal of residual or exogenous estrogen activity. In a woman with PCOS or obesity, elevated E1 can explain symptoms like irregular bleeding, breast tenderness, or difficulty losing weight even when estradiol looks "normal." In perimenopause, a rising E1-to-E2 ratio is one of the earliest hormonal shifts.

How Estrone Is Made

Your body produces E1 through two main pathways. The ovaries secrete it directly during your reproductive years. Fat (adipose) tissue, muscle, skin, and the adrenal glands convert androgens, especially androstenedione, into E1 via an enzyme called aromatase [1]. This peripheral aromatization is why body composition matters so much to your estrogen profile. A woman with higher adiposity will generally have higher E1, regardless of menopausal status.

E1 vs. E2: Why Both Numbers Matter

E2 is roughly 10-80 times more potent at the estrogen receptor than E1, depending on the tissue [2]. But E1 is not inactive. It binds estrogen receptors, drives endometrial proliferation, and affects breast tissue. In the years after menopause, E1 can accumulate to levels that stimulate tissue even when E2 appears low or undetectable. That is why some postmenopausal women with elevated E1 still experience estrogenic symptoms such as breast swelling or unexpected uterine bleeding.

Reference Ranges by Life Stage

Labs report "normal" based on population distributions, not on what makes women feel well or reduces disease risk. The table below compares standard lab cutoffs with the functional ranges that appear in clinical menopause and endocrinology practice.

| Life Stage | Standard Lab Reference | Functional / Clinical Target | |---|---|---| | Reproductive years, follicular phase | 37-138 pg/mL | 50-120 pg/mL | | Reproductive years, luteal phase | 36-170 pg/mL | 50-150 pg/mL | | Perimenopause | 40-170 pg/mL (variable) | Interpret alongside E2, FSH | | Postmenopause (no HRT) | 17-200 pg/mL | 30-100 pg/mL | | Postmenopause (on oral estrogen HRT) | varies by dose | depends on product/route |

These ranges are derived from Endocrine Society reference intervals and Mayo Clinic laboratory data cited in clinical reviews [3]. The "functional target" column reflects the range most often used by menopause practitioners in symptom-guided care, not a single published guideline standard.

Why "Normal" Is Not the Same as "Optimal"

A postmenopausal woman with an E1 of 190 pg/mL is technically within the standard lab range. But that level reflects significant peripheral aromatization, usually from adipose tissue, and may explain persistent breast tenderness, endometrial thickening on ultrasound, or estrogen-dominant symptoms. Conversely, an E1 of 19 pg/mL is also within range but may correlate with bone loss, vaginal dryness, and vasomotor symptoms in a woman who expected her menopause transition to be mild.

The Menopause Society (formerly NAMS) has noted that hormone levels alone should not drive treatment decisions but that they provide important context when symptoms are ambiguous [4]. That means your E1 result should always be read alongside your symptoms, your E2, your FSH, and your clinical picture.

Estrone Across Your Life Stages

Reproductive Years

During your menstrual cycle, estradiol does most of the hormonal heavy lifting. Estrone runs quietly in the background, roughly tracking the follicular phase rise and fall of E2. In this stage, an isolated E1 test is rarely ordered unless a clinician is working up anovulation, adrenal dysfunction, or unexplained estrogenic symptoms in a woman whose E2 looks normal.

If you have PCOS, E1 deserves attention. Women with PCOS have significantly higher androstenedione levels, and aromatase converts that androstenedione into E1 in peripheral tissue [5]. The result is a state of unopposed estrogen stimulation to the endometrium, which, over years, raises the risk of endometrial hyperplasia. A 2019 systematic review in Fertility & Sterility found that women with PCOS have a roughly three-fold higher risk of endometrial cancer than age-matched controls [6]. Estrone is part of the mechanistic story.

Perimenopause

Perimenopause is the stage most underserved by a single E1 measurement. Ovarian output becomes erratic. E2 can swing from very high to very low within a single cycle. E1 tends to rise relative to E2 during this transition because peripheral aromatization continues while ovarian production falters.

The ratio of E1 to E2 (sometimes written E1:E2) can be more informative than either number alone. A rising E1:E2 ratio is a recognized sign of the menopause transition [7]. If you are in your mid-40s, still cycling but noticing hot flushes, sleep disruption, or new-onset breast tenderness, an E1:E2 ratio along with FSH and a careful symptom history gives your clinician more to work with than E2 alone.

Postmenopause: When E1 Becomes the Story

After your final menstrual period, ovarian estradiol production drops to near zero. Estrone, produced in fat and adrenal tissue, becomes the dominant estrogen in your body. Postmenopausal serum E1 concentrations typically range from 17 to 200 pg/mL, compared to E2 levels that often fall below 20 pg/mL [8].

This shift matters for several reasons. E1 at the higher end of the postmenopausal range, especially above 120-150 pg/mL, has been associated with increased breast tissue density and has been studied as a risk marker for hormone receptor-positive breast cancer. The Women's Health Initiative observational data showed that higher postmenopausal endogenous estrogen levels, including estrone, correlated with increased breast cancer risk, with women in the top quintile of E1 having roughly double the risk of those in the lowest quintile [9].

On the other side, very low E1 after menopause contributes to:

• Genitourinary syndrome of menopause (GSM): vaginal dryness, recurrent UTIs, painful intercourse
• Accelerated bone loss and osteoporosis risk
• Vasomotor symptoms that persist beyond the early menopause years
• Mood and cognitive changes (though causality remains debated)

If You Are on Hormone Therapy

Monitoring E1 on hormone therapy (HRT) depends on the preparation. Oral estrogen (estradiol tablets or conjugated equine estrogens) is heavily metabolized in the gut and liver, producing large amounts of estrone as a first-pass metabolite. Women on oral estradiol have E1:E2 ratios of roughly 5:1 to 10:1, whereas transdermal estradiol maintains a ratio closer to the physiological 1:1 seen in the reproductive years [10]. This is one clinical reason some menopause practitioners prefer transdermal routes, particularly in women with elevated baseline E1 or clotting risk.

What High Estrone Means for You

High E1 (above 150-200 pg/mL postmenopause, or consistently elevated in reproductive-age women who are not periovulatory) usually points to one or more of the following:

Excess Adipose Aromatization

This is the most common driver of elevated E1 in all life stages. Adipose tissue expresses aromatase constitutively, meaning it converts androgens to estrogens around the clock. Higher body fat mass equals higher peripheral estrogen production. A study in the Journal of Clinical Endocrinology & Metabolism found that each 10-unit increase in BMI was associated with a 12-15% increase in circulating E1 in postmenopausal women not using HRT [11].

Ovarian or Adrenal Androgen Excess

If your androstenedione or DHEA-S is elevated, aromatase has more substrate to work with, and E1 rises as a downstream result. This is the PCOS pattern discussed earlier, but it can also occur with adrenal hyperplasia or androgen-secreting tumors (rare but important to exclude).

Exogenous Estrogen Exposure

Oral estrogen therapy reliably raises E1. If your E1 is higher than expected on a given HRT dose, reviewing the route and formulation is a reasonable first step before adjusting dose.

What High E1 Can Look Like Clinically

Symptoms overlap considerably with generalized estrogen excess:

• Breast swelling or cyclic breast pain
• Bloating and fluid retention
• Irregular or heavy bleeding (in women who still have a uterus and are perimenopausal)
• Mood changes, particularly irritability or anxiety
• In postmenopause, unexplained uterine bleeding on ultrasound, or endometrial thickening above 4 mm, warrants evaluation per ACOG Practice Bulletin guidance [12]

What Low Estrone Means for You

Low E1 in postmenopause (below 17-30 pg/mL) reflects minimal peripheral estrogen production. Low E1 in a woman who still has regular cycles and is not perimenopausal is less common and should prompt investigation of ovarian reserve, hypothalamic-pituitary function, or eating disorder-related hypothalamic suppression.

Consequences of Chronically Low E1 After Menopause

The skeleton is exquisitely sensitive to estrogen. The Endocrine Society's clinical practice guideline on osteoporosis in postmenopausal women notes that estrogen deficiency is the primary driver of the rapid bone loss that occurs in the first 5-7 years after menopause, with women losing 1-3% of bone mineral density per year during this window [13]. Low E1 in a thin, postmenopausal woman with no exogenous estrogen provides almost no protection against this loss.

Other consequences of very low E1:

• Severe GSM symptoms unresponsive to non-hormonal treatments
• Increased fracture risk, particularly vertebral and hip
• Accelerated cardiovascular risk (though the mechanism is complex and debated)
• Persistent vasomotor symptoms beyond the typical 7-year window

Low E1 in Younger Women

In a premenopausal woman, low E1 alongside low E2 and elevated FSH suggests premature ovarian insufficiency (POI). ACOG defines POI as ovarian dysfunction before age 40, affecting approximately 1 in 100 women [14]. Women with POI face bone and cardiovascular risks decades earlier than their peers, and estrogen replacement (not just oral contraceptives) is generally recommended until the average age of natural menopause around 51.

How to Lower High Estrone

Reducing elevated E1 is generally about reducing the substrate for peripheral aromatization or the stimulation of that aromatase enzyme.

Body Composition Changes

Reducing adipose tissue reduces aromatase activity. Even modest weight loss of 5-10% of body weight in overweight postmenopausal women can significantly lower circulating estrone, as shown in the Women's Health Initiative dietary modification trial data [15]. Exercise independently reduces aromatase activity in adipose tissue. Resistance training has the added benefit of increasing lean mass while reducing fat mass, shifting the body composition in a direction that lowers E1 production.

Diet: Fiber, Phytoestrogens, and Cruciferous Vegetables

High-fiber diets reduce enterohepatic recirculation of estrogens. Fiber binds estrogen metabolites in the gut and reduces reabsorption. Cruciferous vegetables (broccoli, Brussels sprouts, kale) contain indole-3-carbinol, which shifts estrogen metabolism toward less potent hydroxylated metabolites. These are supportive strategies, not replacements for medical management when E1 is significantly elevated.

Switching Hormone Therapy Route

If elevated E1 is driven by oral estrogen HRT, switching to transdermal estradiol bypasses first-pass hepatic metabolism and reduces the E1:E2 ratio substantially. This is a clinical conversation with your prescribing clinician, not a self-directed change.

Aromatase Inhibitors

Aromatase inhibitors (AIs) such as anastrozole and letrozole are used in postmenopausal women with hormone receptor-positive breast cancer to suppress E1 production aggressively. Outside oncology, AIs are occasionally used off-label in fertility treatment for PCOS or in gender-affirming care. They are not a general strategy for lowering mildly elevated E1 in an otherwise healthy woman.

How to Raise Low Estrone

Estrone itself is not a commonly prescribed therapy. Clinicians treat low estrogen status by replacing estradiol, which then equilibrates with estrone through normal metabolism.

Hormone Therapy for Postmenopausal Women

The Menopause Society's 2023 position statement confirms that hormone therapy remains the most effective treatment for menopause-related symptoms and for prevention of bone loss in women under 60 or within 10 years of menopause onset [16]. Restoring estradiol raises E1 secondarily. Route of delivery influences how much E1 accumulates.

Estrogen Replacement for POI

Women with premature ovarian insufficiency need estrogen replacement, generally at doses higher than those used for symptom management in typical menopause, to approximate physiological premenopausal levels. Standard-dose hormone therapy is often insufficient for bone protection in women with POI in their 30s.

Lifestyle Factors

In perimenopausal women with low-normal E1, soy isoflavones have weak estrogenic activity and some women report modest symptom improvement, though the clinical evidence for raising serum E1 via diet alone is limited. Maintaining a healthy weight and avoiding excessive caloric restriction support adrenal androgen production, which is the substrate for peripheral E1 synthesis.

Pregnancy, Lactation, and Estrone

This section addresses estrone in the context of conception, pregnancy, and the postpartum period.

Estrone in Pregnancy

Estrone rises substantially during pregnancy, as the fetoplacental unit produces large amounts of all three estrogens. By the third trimester, total estrogen production is 100-fold higher than in the non-pregnant state. Measuring E1 in pregnancy is not a standard clinical test. Estriol (E3) is the estrogen measured in maternal serum screening (the "triple" or "quad" screen) because it reflects fetal and placental function, not E1.

There is no intervention to adjust E1 levels during a healthy pregnancy. Elevated or low E1 during pregnancy is not an actionable clinical finding in routine obstetric care.

Estrone and Fertility Workup

In a fertility evaluation, E2 (not E1) is the standard estrogen measured on cycle day 2-3 alongside FSH to assess ovarian reserve. E1 is not part of the ASRM-recommended baseline fertility panel. If a clinician includes it, the context is usually investigation of estrogen excess (elevated E1 from peripheral aromatization in obesity or PCOS) that may be affecting the cycle.

Postpartum and Lactation

After delivery, estrogen levels fall sharply. Breastfeeding suppresses ovarian estrogen production via elevated prolactin. This creates a hypoestrogenic state similar to menopause, with GSM symptoms, vaginal dryness, and low libido common in lactating women. Serum E1 in a fully breastfeeding woman is typically low. This is physiologically normal and expected. Local vaginal estrogen (very low-dose topical estradiol or estriol cream) is considered safe during lactation by most guidelines and can relieve GSM symptoms without meaningfully affecting breast milk [17, 18].

Systemic estrogen to raise E1 or E2 during lactation is generally avoided because estrogen suppresses milk supply.

Contraception Note

Estrone testing has no direct contraceptive implication. However, combined hormonal contraceptives (the pill, patch, ring) contain synthetic estrogens (ethinyl estradiol) and suppress ovarian estrogen production. Women on hormonal contraceptives will have suppressed E1 and E2 from the ovaries, and any estrone detected reflects peripheral aromatization or the contraceptive's own estrogenic effect. Testing estrone while on combined hormonal contraceptives gives a picture that does not reflect your baseline hormonal status.

Who Should Test Estrone, and Who Probably Does Not Need It

The following framework reflects clinical practice patterns, not a single published guideline, and is intended to guide the conversation with your clinician.

Estrone testing is most likely to add clinical value if you are:

• Postmenopausal with unexplained estrogenic symptoms (breast tenderness, uterine bleeding, endometrial thickening) and low or undetectable E2
• Postmenopausal on oral HRT with unexplained symptom changes or suspected over-replacement
• Perimenopausal and your E2 fluctuates widely; E1 provides a more stable picture of total estrogen burden
• Diagnosed with PCOS and have persistent anovulation or endometrial concerns
• In evaluation for premature ovarian insufficiency (alongside E2, FSH, AMH)
• Assessed for estrogen-related breast cancer risk (as part of an expanded hormonal panel, not alone)

Estrone testing is likely to add little if you are:

• A reproductive-age woman with regular cycles and no specific complaint
• Pregnant (E1 is not clinically actionable in routine pregnancy care)
• Using combined hormonal contraceptives (results do not reflect your basal state)
• Asking about menopause symptoms when you have not yet had E2 and FSH measured first

Evidence Gaps: What We Do Not Know Yet About Estrone in Women

Women have been under-represented in hormone research for decades. Most of what we know about E1 and disease risk comes from the Women's Health Initiative (WHI) and epidemiological cohorts that enrolled primarily white, postmenopausal women over 50. There are real gaps:

• Functional optimal E1 ranges for women in their 40s navigating perimenopause are not established by randomized trial data.
• The E1:E2 ratio as a clinical decision tool is supported by physiological reasoning and observational data, not by prospective interventional trials showing improved outcomes.
• Data on optimal E1 in transgender women or in women with surgically induced menopause are sparse.
• The interaction between E1 and brain health (cognition, depression risk) across the menopause transition is an active area of research with no definitive answers yet.

When your clinician interprets your E1 result, they are drawing on population reference ranges, physiological principles, and clinical experience, not a single evidence-based target number. That context is worth knowing.